Chronic curcumin treatment normalizes depression-like behaviors in mice with mononeuropathy: involvement of supraspinal serotonergic system and GABAA receptor
- 987 Downloads
Comorbid depression is commonly observed in individuals who suffer from neuropathic pain, which necessitates improved treatment. Curcumin, a phenolic compound derived from Curcuma longa, possesses both antinociceptive and antidepressant-like activities in animal studies, suggesting its possible usefulness in treating this comorbidity.
We investigated the effect of curcumin on depressive-like behaviors in mice with mononeuropathy, and explored the mechanism(s).
Chronic constriction injury (CCI) was produced by loosely ligating the sciatic nerves in mice. The nociceptive behaviors were examined using Hargreaves test, and the depressive-like behaviors were determined by forced swim test (FST) and tail suspension test (TST).
After CCI injury, the neuropathic mice developed nociceptive and depressive-like behaviors, as shown by thermal hyperalgesia in Hargreaves test and protracted immobility time in FST and TST. Chronic treatment of neuropathic mice with curcumin (45 mg/kg, p.o., twice per day for 3 weeks) corrected their exacerbated nociceptive and depressive-like behaviors, which was abolished by chemical depletion of brain serotonin rather than noradrenaline. The paralleled antinociceptive and antidepressant-like actions of curcumin seem to be pharmacologically segregated, since intrathecal and intracerebroventricular injection of methysergide, a nonselective 5-HT receptor antagonist, separately counteracted the two actions of curcumin. Further, this antidepression was abrogated by repeated co-treatment with 5-HT1A receptor antagonist WAY-100635 and greatly attenuated by acute co-treatment with GABAA receptor antagonist bicuculline.
Curcumin can normalize the depressive-like behaviors of neuropathic mice, which may be independent of the concurrent analgesic action and possibly mediated via the supraspinal serotonergic system and downstream GABAA receptor.
KeywordsCurcumin Depression Neuropathic pain Serotonin GABAA
This work was supported by the K.C. Wong Magna Fund in Ningbo University, National Natural Science Foundation of China (81201050), Natural Science Foundation of Zhejiang Province (LY12H09002), and Innovative Research Team of Ningbo (2009B21002).
Conflict of interest
The authors declare no conflicts of interest.
- De Souza MM, Pereira MA, Ardenghi JV, Mora TC, Bresciani LF, Yunes RA, Delle Monache F, Cechinel-Filho V (2009) Filicene obtained from Adiantum cuneatum interacts with the cholinergic, dopaminergic, glutamatergic, GABAergic, and tachykinergic systems to exert antinociceptive effect in mice. Pharmacol Biochem Behav 93:40–46PubMedCrossRefGoogle Scholar
- Duarte FS, Lach G, Martins PR, Romeiro GA, de Lima TC (2008) Evidence for the involvement of the monoaminergic system in the antidepressant-like action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a, d] cycloheptane in mice evaluated in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 32:368–374PubMedCrossRefGoogle Scholar
- Marchand F, Ardid D, Chapuy E, Alloui A, Jourdan D, Eschalier A (2003) Evidence for an involvement of supraspinal delta- and spinal mu-opioid receptors in the antihyperalgesic effect of chronically administered clomipramine in mononeuropathic rats. J Pharmacol Exp Ther 307:268–274PubMedCrossRefGoogle Scholar
- Shen Q, Lal R, Luellen BA, Earnheart JC, Andrews AM, Luscher B (2010) Gamma-aminobutyric acid-type A receptor deficits cause hypothalamic–pituitary–adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. Biol Psychiatry 68:512–520PubMedCentralPubMedCrossRefGoogle Scholar
- Tyagarajan SK, Ghosh H, Yévenes GE, Nikonenko I, Ebeling C, Schwerdel C, Sidler C, Zeilhofer HU, Gerrits B, Muller D, Fritschy JM (2011) Regulation of GABAergic synapse formation and plasticity by GSK3beta-dependent phosphorylation of gephyrin. Proc Natl Acad Sci U S A 108:379–384PubMedCentralPubMedCrossRefGoogle Scholar
- Villarinho JG, Pinheiro KD, Pinheiro FD, Oliveira SM, Machado P, Martins MA, Bonacorso HG, Zanatta N, Fachinetto R, Ferreira J (2013) The antinociceptive effect of reversible monoamine oxidase-A inhibitors in a mouse neuropathic pain model. Prog Neuropsychopharmacol Biol Psychiatry 44:136–142PubMedCrossRefGoogle Scholar